UNC Health Medication Formulary
Add Formweb to your mobile device
UNC Health Medication Formulary
System Formulary Update
Filgrastim Agents
Situation
The filgrastim agents class review and formulary standardization was approved by the System Pharmacy & Therapeutics Committee in May 2021.
Background
The following medications were reviewed: filgrastim (Neupogen), tbo-filgrastim (Granix), filgrastim-aafi (Nivestym), and filgrastim-sndz (Zarxio)
Assessment/Recommendation
Changes effective: Tuesday July 27, 2021
System P&T voted to include the following products on the UNC Health Care System Drug Formulary:
- tbo-filgrastim (Granix) with no restrictions
- filgrastim-aafi (Nivestym) with use restricted to the outpatient, clinic setting only for patients who were previously on Nivestym or patients with payer policies that require Nivestym or do not cover Granix
- filgrastim-sndz (Zarxio) with use restricted to the outpatient, clinic setting only for patients who were previously on Zarxio or patients with payer policies that require Zarxio or do not cover Granix
System P&T voted to exclude the following products on the UNC Health Care System Drug Formulary:
- filgrastim (Neupogen)
- Patients currently on Neupogen can continue the course of therapy to completion. New starts of filgrastim will be limited to the products included on the UNC Health Care System Drug Formulary.
Note: Stock of these formulary products may vary at individual entities